Biogen Inc. (BIIB) Financials

BIIB Assets vs Liabilities

DateAssetsLiabilities
March 31, 2026 29.5 billion 10.8 billion
Dec. 31, 2025 29.4 billion 11.2 billion
Sept. 30, 2025 29.2 billion 11.0 billion
June 30, 2025 28.3 billion 10.7 billion

BIIB Free Cash Flow and Stock based compensation

Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 696.7 million 84.0 million
Dec. 31, 2025 555.9 million 59.6 million
Sept. 30, 2025 1.2 billion 75.3 million
June 30, 2025 144.3 million 74.9 million

BIIB Net Income

Graph available only for paid members. Upgrade to see it.
DateNet Income
March 31, 2026 319.5 million
Dec. 31, 2025 -48.9 million
Sept. 30, 2025 466.5 million
June 30, 2025 634.8 million

BIIB Cash and Debt

Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 4.3 billion 6.3 billion 273.4 million
Dec. 31, 2025 3.8 billion 6.6 billion 290.4 million
Sept. 30, 2025 4.0 billion 6.3 billion 305.0 million
June 30, 2025 2.8 billion 6.3 billion 310.9 million

BIIB Shares Outstanding

Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 148.4 million
Dec. 31, 2025 146.7 million
Sept. 30, 2025 147.1 million
June 30, 2025 145.9 million

BIIB Expenses

Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 51.2 million 573.0 million 607.3 million -
Dec. 31, 2025 43.9 million 509.3 million 683.0 million -
Sept. 30, 2025 46.2 million 369.6 million 594.8 million -
June 30, 2025 16.6 million 529.9 million 581.3 million -

BIIB Cost of Revenue

Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 2.5 billion 661.0 million
Dec. 31, 2025 2.3 billion 496.3 million
Sept. 30, 2025 2.5 billion 876.6 million
June 30, 2025 2.6 billion 946.2 million

BIIB Revenue by Segment

Graph available only for paid members. Upgrade to see it.

BIIB

Price: $201.08

52 week price:
121.05
219.72

Payout Ratio Range:
51.72%
88.24%

Earnings Per Share: 9.30 USD

P/E Ratio: 20.34

Exchange: NMS

Sector: Healthcare

Industry: Drug Manufacturers - General

Country: United States

Volume: 789100

Ebitda: 1.6 billion

Market Capitalization: 31.9 billion

Links: